Company

AstraZeneca

Official Name: AstraZeneca plc

Headquarters: Cambridge, United Kingdom

Founded: 6 April 1999

Employees: 83,100

CEO: Mr. Pascal Soriot D.V.M., M.B.A.

show_chart LSE: AZN -1.54%

Market Cap

£180.79 Billion

GBP as of Jan. 1, 2023

US$217.81 Billion

history Market Cap History

Company Description

AstraZeneca PLC is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. AstraZeneca develops, manufactures, and sells pharmaceuticals and biotechnology products to treat major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

AstraZeneca market capitalization evolution

Evolution of AstraZeneca plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of AstraZeneca plc

Detailed Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Stocks & Indices

AstraZeneca plc has the following listings and related stock indices.


Stock: LSE: AZN

Stock: NASDAQ: AZN

Stock: BCBA: AZN

Stock: BMV: AZNN

Stock: FSX: ZEG

Stock: FSX: ZEGA

Stock: OMX: AZN

Stock: OTC: AZNCF

Stock: XETR: ZEG

Product & Services

Pharmaceutical products

Key People

Leif Johansson (Chairman) Pascal Soriot (CEO)

Financials

Revenue: US$37.417 billion (2021)

Operating income: US$1.056 billion (2021)

Net income: US$0.115 billion (2021)


Total assets: US$105.363 billion (2021)

Total equity: US$39.287 billion (2021)

Details

Headquarters:

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge, CB2 0AA

United Kingdom

Phone: 44 20 3749 5000